Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
ChromaDex Corp. (NASDAQ: CDXC), transitioning to the name Niagen Bioscience, Inc. with a new Nasdaq ticker symbol NAGE, generates a steady flow of news centered on NAD+ science and healthy aging. As the self-described global authority on nicotinamide adenine dinucleotide (NAD+), the company regularly issues updates on its Niagen ingredient, Tru Niagen supplement brand, and pharmaceutical-grade Niagen IV and injection products.
News for CDXC often includes financial results and outlooks, where ChromaDex reports quarterly and annual net sales, gross margins, net income, and cash flow metrics, along with commentary on trends in Tru Niagen and Niagen ingredient sales. These releases may also discuss expectations for future revenue growth, margin performance, and planned investments in research, development, and marketing.
Investors can also expect corporate and investor relations announcements, such as participation in healthcare and growth company conferences, investor summits, and panel discussions on longevity and supplementation. These events typically feature company management presenting ChromaDex’s strategy, financial performance, and updates on its NAD+ research and product pipeline.
Another key category of news involves product and partnership developments. ChromaDex has announced the expansion of Niagen IV and related pharmaceutical-grade Niagen products across wellness clinic networks, as well as collaborations where Niagen serves as a hero ingredient in third‑party longevity supplements. The company also highlights recognition in industry lists and awards related to health products and business impact.
Finally, ChromaDex issues scientific and regulatory updates, including information about FDA designations for nicotinamide riboside in rare disease indications and progress toward regulatory milestones. For anyone tracking CDXC, or its successor symbol NAGE, this news feed offers a consolidated view of the company’s financial performance, clinical and regulatory progress, commercial expansion, and branding evolution around Niagen and NAD+ science.
ChromaDex Corp. (NASDAQ: CDXC) appointed Dr. Vilhelm Bohr to its Scientific Advisory Board. Dr. Bohr, a leading researcher in aging and neurodegenerative diseases, has over 590 publications and specialized in the effects of nicotinamide riboside (NR) on age-related conditions. His past research through ChromaDex's External Research Program has resulted in significant findings regarding NR's role in mitochondrial dysfunction and neurodegeneration. Dr. Bohr aims to explore further benefits of NR at ChromaDex.
ChromaDex Corp. (NASDAQ:CDXC) appointed Brianna Gerber as the new Chief Financial Officer, effective January 1, 2023. Gerber has over 20 years of experience in finance and investor relations, having served as Senior VP of Finance at ChromaDex since August 2022. CEO Rob Fried praised her leadership and commitment to achieving an EBITDA-positive business. Gerber expressed excitement about leading the company towards profitable growth and operational efficiency.
ChromaDex Corp. (NASDAQ:CDXC) announced new findings supporting the efficacy of its proprietary Niagen® (nicotinamide riboside or NR) in enhancing neurodegenerative biomarkers associated with aging. A recent peer-reviewed study found that NR supplementation significantly increased NAD+ levels in neuron-derived extracellular vesicles and reduced biomarkers linked to Alzheimer’s disease, like Aβ42. This research builds on previous studies supporting NR’s benefits for cognitive health and sets the stage for future trials, including one focused on older adults with mild cognitive impairment.
ChromaDex Corp. (NASDAQ:CDXC) announced that the U.S. FDA has determined that nicotinamide mononucleotide (NMN) cannot be marketed as a dietary supplement, as it has been first investigated as a drug since November 4, 2022. This decision impacts ChromaDex's NMN offerings, while its proprietary ingredient Niagen®, a form of nicotinamide riboside (NR), remains a viable NAD+ precursor backed by over 20 clinical studies. ChromaDex continues its focus on NAD+ research and has established extensive partnerships for its CERP™ program.
ChromaDex Corp. (NASDAQ:CDXC) reported Q3 2022 net sales of $17.1 million, reflecting a 1% decline from Q3 2021. Strong gross margin stood at 59.8%. The net loss improved to $1.0 million or $(0.01) per share, a significant reduction from $8.8 million in Q3 2021. Adjusted EBITDA loss of $1.2 million shows a $5.1 million improvement. The company anticipates high single-digit revenue growth for 2022, targeting cash flow break-even in Q4. Strategic partnerships in China and with Nestlé Health Science were secured.
ChromaDex Corp. (NASDAQ:CDXC) will host a conference call on November 2, 2022, at 4:30 p.m. ET to discuss its third quarter financial results for the period ending September 30, 2022. The results will be announced in a press release after market hours on the same day. Interested participants are advised to dial in 10 minutes early, with the toll-free number being 1-888-330-2446 and Conference ID 4126168. A replay will be available from 7:30 p.m. ET on November 2 to November 9, 2022.
ChromaDex Corp. (NASDAQ:CDXC) announced that its supplement, Tru Niagen®, received the “Most Popular Brand of the Year Award” at the China International Natural Health & Nutrition Expo on September 20, 2022. This recognition highlights the product's robust research backing and expanding market presence, especially in the cross-border e-commerce sector in China. With a consumer base over 264 million aged 60 and above in China, the demand for healthy aging products is growing. ChromaDex aims to solidify its market leadership through partnerships and enhanced distribution channels.
ChromaDex has announced a new long-term commercial license and supply agreement with Nestlé Health Science that expands their previous supply agreement to include dietary supplements. The deal features a $1.975 million initial purchase commitment for the ingredient Niagen®, along with potential future milestone payments and tiered royalties based on sales. In addition, Nestlé is purchasing 3,816,794 shares of ChromaDex at $1.31 each for gross proceeds of $5 million.
ChromaDex Corp. (NASDAQ:CDXC) announced promising findings from a clinical study published in the Journal of the American College of Cardiology. The study evaluated the safety and tolerability of the company's proprietary Niagen® (nicotinamide riboside or NR) in Stage C heart failure patients. Key results showed that high-dose NR was well-tolerated, nearly doubling whole blood NAD+ levels, enhancing mitochondrial function, and reducing inflammatory markers. This milestone trial opens avenues for future research into NR's therapeutic potential in heart failure.
ChromaDex has established a joint venture to expedite the approval of Tru Niagen® registration in China ("Blue Hat" approval). An investment of
FAQ
What is the current stock price of Chromadex (CDXC)?
What is the market cap of Chromadex (CDXC)?
